Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents.
Michi
M
Tanaka
Department of Pharmacovigilance, and Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical Dental University;
Ryoko
R
Sakai
Department of Pharmacovigilance, and Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical Dental University, and Clinical Research Center, Tokyo Medical Dental University Hospital;
Ryuji
R
Koike
Department of Pharmacovigilance, and Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical Dental University, Tokyo, Japan. mharigai.mpha@tmd.ac.jp.
Masayoshi
M
Harigai
D000068879:Adalimumab / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D045363:Pneumocystis carinii / Q000302:isolation & purification*; D011020:Pneumonia, Pneumocystis / Q000209:etiology*
D018501:Antirheumatic Agents; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept